CALIBRATION: An Exploratory Study in Patients With Advanced Oesophageal Malignancies Receiving MEDI4736 (Durvalumab), Investigating Whether Early Changes in Circulating Tumour DNA Can Predict Tumour Response
Latest Information Update: 29 Apr 2025
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms CALIBRATION
Most Recent Events
- 24 Apr 2025 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
- 09 Feb 2023 Planned End Date changed from 1 Feb 2022 to 1 Jun 2024.
- 21 Sep 2020 Interim data results (n=7) presented at the 45th European Society for Medical Oncology Congress